# Hongfeng Investment Management

> Hongfeng Investment Management is a VC fund in Qingpu backing Biotechnology and Health Care. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Qingpu, China
- Total investments: 7
- Last investment: Nov 2024
- Lead investor: 14%
- Last updated: Aug 2026

Hongfeng Investment Management is an investment firm.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 57% |
| Health Care | 2 | 29% |
| Medical | 1 | 14% |
| Big Data | 1 | 14% |
| Software | 1 | 14% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 43% |
| Seed | 2 | 29% |
| Angel | 1 | 14% |
| Series B | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Dianxin Technology | Dianxin Technology is a company that manufactures microLED and chiplet process measurement equipment. Dianxin Technology has created non-reference position measuring and defect detection equipment for mass transfer, giving tools for managing MicroLED yield. | $14M | Series A | Nov 07, 2024 |  |
| Leadopharma | Leadopharma engages in the research and development of drugs targeting pain, epilepsy, depression, and neurodegenerative diseases. Leadopharma has established a complete pharmaceutical chemistry and ion channel drug research and development platform and team, which can independently carry out drug synthesis, activity screening, and early safetypharmacology research for ion channel targets. |  | Series A | Aug 07, 2023 |  |
| Zilixir Biotech | Zilixir Biotech develops a new protein design technology that offers possibilities for human exploration of the complex life sciences. SWORD™ protein design technology integrates binding pockets, new drug skeleton design, activity prediction, ADME/T prediction, etc., and has had some achievements in these areas, fully demonstrating theeffectiveness of protein design. | $14.1M | Series A | May 25, 2023 |  |
| Jianxin Biotech | Jianxin Bio focuses on new monoclonal antibody drugs, CAR-T (Chimeric Antigen Receptor T Cell) technology innovation. |  | Series B | Mar 20, 2023 |  |
| Shuxin Network | Shuxin Network is a big data service solution provider focusing on cloud data platforms. The company can provide one-stop services from data aggregation to data services, efficient modeling, intelligent operation and maintenance, and intelligent analysis, allowing data from collection to presentation. , From the analysis to the driving application,the high-quality combination is obtained, and the overall competitiveness of the enterprise is improved. |  | Seed | Aug 25, 2022 |  |
| T-Maximum | T-Maximum develops CAR-T cell therapies for the treatment of brain tumors. T-Maximum's gene-editing allogeneic immune cell therapy adopts the version 3.0 program with completely independent intellectual property rights to realize allogeneic universal CAR-T therapy and solve the risk of graft-versus-host disease and rejection of allogeneicimmune cells. |  | Angel | Aug 20, 2021 |  |
| Leadopharma | Leadopharma engages in the research and development of drugs targeting pain, epilepsy, depression, and neurodegenerative diseases. Leadopharma has established a complete pharmaceutical chemistry and ion channel drug research and development platform and team, which can independently carry out drug synthesis, activity screening, and early safetypharmacology research for ion channel targets. |  | Seed | Jul 01, 2021 |  |

7 of 7 investments shown.

## Co-investors
- [Shanghai Biomedical Industrial Equity Investment Fund](https://shizune.co/investors/profile/shanghai-biomedical-industrial-equity-investment-fund) — VC Fund, 2 deals together
- [Fangyu Venture Capital](https://shizune.co/investors/profile/fangyu-venture-capital) — VC Fund, 1 deal together
- [Haibang Capital](https://shizune.co/investors/profile/haibang-capital) — VC Fund, 1 deal together
- [Hongke Baishi](https://shizune.co/investors/profile/hongke-baishi) — VC Fund, 1 deal together
- [Huimei Capital](https://shizune.co/investors/profile/huimei-capital) — VC Fund, 1 deal together
- [Life Capital](https://shizune.co/investors/profile/life-capital) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [East Ventures](https://shizune.co/investors/profile/east-ventures) — VC Fund
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund

## Featured in investor lists
- [Life Science Investors in China](https://shizune.co/investors/life-science-investors-china)
- [Life Science VC Funds in China](https://shizune.co/investors/life-science-vc-funds-china)
- [Life Science Investors in Asia](https://shizune.co/investors/life-science-investors-asia)
- [Life Science VC Funds in Asia](https://shizune.co/investors/life-science-vc-funds-asia)

## FAQ

### What does Hongfeng Investment Management invest in?

Hongfeng Investment Management invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Seed stage. Most of the 7 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Hongfeng Investment Management last invest?

The most recent investment recorded for Hongfeng Investment Management closed in Nov 2024. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co